The latest update is out from Avidity Biosciences Inc (RNA).
Avidity Biosciences, Inc. has appointed Simona Skerjanec as a new director, effective May 14, 2024, following a vacancy left by Eric Mosbrooker. With an impressive track record in the pharmaceutical industry, including senior roles at Roche and The Medicines Company, Skerjanec brings a wealth of experience to the role. In addition to her directorship, she is set to receive stock options and cash compensation as per the Company’s compensation program for non-employee directors, as well as entering into a standard indemnification agreement with the Company. Skerjanec is recognized as an independent director, meeting Nasdaq’s listing requirements.
Learn more about RNA stock on TipRanks’ Stock Analysis page.
